Organisation paid for research Program year 2025 Source: CMS Open Payments

Galenos Research

Neither a doctor nor a teaching hospital

Research payments

$231,181

51 payments

Through program year 2025, Galenos Research is reported as receiving $231,181 in research payments, across 51 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$21,618	2
2024	Research	$15,560	2
2023	Research	$16,420	3
2022	Research	$24,024	3
2021	Research	$39,162	2
2020	Research	$37,785	8
2019	Research	$76,612	31

Breakdown

Who paid Research payments · program years 2019–2025

Eli Lilly and Company $136,881 14 payments
Novo Nordisk AS $94,156 34 payments
Pfizer Inc. $144 3 payments

Studies the money was for Research payments · program years 2019–2025

The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) $119,900 10 payments
Nn9536-4374 $50,234 28 payments
Nn9068-4228 $19,571 1 payment
The Effect of Tirzepatide Versus Dulaglutide on Major Adverse Cardiovascular Events in Patients With Type 2 Diabetes (Surpass Cvot) $16,390 2 payments
Nn2211-4232 $10,566 3 payments
Nn9535-4270 $7,541 1 payment
Nn9924-4280 $6,243 1 payment
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $562 1 payment
A Phase 3 Randomized Doubleblind Activecontrolled Multicenter Study of the Longterm Safety and Efficacy of Subcutaneous Administration of Tanezumab in Subjects With Osteoarthritis of the Hip Or Knee $144 3 payments
A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $30 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.